01276nas a2200253   4500000000100000008004100001260001300042653001000055653002600065653002400091653004100115653001100156653001100167653002300178653001200201653002200213100001500235700001900250245006500269300001500334490000700349520065200356022001401008       2008                            d  c2008 Apr10aAdult10aAntidepressive Agents10aConversion Disorder10aDrug Resistance, Multiple, Bacterial10aFemale10aHumans10aLeprostatic Agents10aleprosy10aTreatment Outcome1 aLegaspi PS1 aAbad Venida ML00aConversion disorder: "an adverse reaction" to watch out for.  a239-43, vi0 v263 a<p>A subject was enrolled in a multicenter, double-blinded clinical trial of ofloxacin-containing multidrug therapy for leprosy by the World Health Organization in 1992 and she developed multiple physical symptoms a few hours after taking the regimen. Physical examination and laboratory work-ups could not support a medical diagnosis and she was eventually dropped from the study. Decoding revealed that she belonged in the control group given the World Health Organization/multiple drug therapy-multibacillary regimen. In the course of treatment, she was diagnosed with conversion disorder and was subsequently treated with an antipsychotic.</p>  a0733-8635